Hepatic dysfunction as the presenting feature of acute lymphoblastic leukemia

American Journal of Pediatric Hematology/Oncology

Volumn 23, Issue 2, 2001, Pages 117-121

  Kelleher, John F ^a   Monteleone, Philip M ^a   Steele, David A ^a   Gang, David L ^a   Angelides, Anastasios G ^a  

^a BAYSTATE MEDICAL CENTER   (United States)

Author keywords

Hepatic dysfunction; Hepatitis; Jaundice; Leukemia

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CASE REPORT; CHILD; CHILDHOOD CANCER; CLINICAL FEATURE; DATA BASE; HUMAN; JAUNDICE; LIVER DYSFUNCTION; LIVER METABOLISM; MALE; MEDICAL INFORMATION; PRACTICE GUIDELINE; PRIORITY JOURNAL;

6-MERCAPTOPURINE; ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; BIOPSY; CHILD, PRESCHOOL; CHOLESTASIS, INTRAHEPATIC; CHROMOSOME DELETION; DAUNORUBICIN; HEPATOMEGALY; HUMANS; LEUKEMIA, PRE-B-CELL; LIVER; LIVER FUNCTION TESTS; MALE; METHOTREXATE; PRACTICE GUIDELINES; PREDNISONE; PROGNOSIS; REMISSION INDUCTION; THROMBOCYTOPENIA; VINCRISTINE;

EID: 0035104846     PISSN: 01928562     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200102000-00010     Document Type: Article

References (13)

1. Devictor D, Tashive C, Fagre M, et al. Early pre-B acute leukemia presenting as fulminant liver failure. J Pediatr Gastroenterol 1996; 22:106-10.
2. Mori T, Sugita K, Suzuki T, et al. Histopathologic features of the biopsied liver at the onset of childhood B-precursor acute lymphoblastic leukemia presenting as severe jaundice. J Pediatr Gastroenterol 1997; 25:354-7.
3. Locasciulli A, Pontisso P, Cavalletto D, et al. Evidence against the role of hepatitis C virus in severe liver damage occurring early in the course of acute leukemia in children. Leuk Lymphoma 1994; 13:119-22.
4. th ed. Philadelphia: W.B. Saunders, 1998:1260.
5. Hutchinson R, Bertolone S, Cooper H, et al. Early marrow response predicts outcome for patients with low risk ALL: Results of CCG-1881. ASCO Proc 1994; 13:319A.
6. Nachman J, Sather HM, Gaynon PS, et al. Augmented Berlin Frankfurt Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy. J Clin Oncol 1997; 15:222-30.
7. Scheinberg IB, Pollock DJ, Collins PW, et al. Pathology of the liver in leukemia and lymphoma. Histopathology 1995; 26:311-21.
8. Alvaro F, Jain M, Morris LL, et al. Childhood acute lymphoblastic leukemia presenting as jaundice. J Pediatr Child Health 1996; 32(5):466-8.
9. Menard DB, Gisselbrecht C, Marty M, et al. Antineoplastic drugs and the liver. Gastroenterology 1980; 78(1):142-64.
10. Reif S, Tano M, Oliverio R, et al. Total parenteral nutrition-induced steatosis: reversal by parenteral lipid infusion. J Parenter Enter Nutr 1991; 15:102-04.
11. Relling MV, Crom WR, Pieper JA, et al. Hepatic drug clearance in children with leukemia: changes in clearance of model substrates during remission-induction therapy. Clin Pharmacol Ther 1987; 41(6):651-60.
12. Sulkes A Collins JM. Reappraisal of some dosage adjustment guidelines (commentary). Cancer Treat Reports 1987; 71:229-32.
13. Pui CH, Carroll AJ, Raimonde SC, et al. Clinical presentation, karyotypic characterization and treatment outcome of childhood acute lymphoblastic leukemia with a nearly haploid or hypodiploid (<45) line. Blood 1990; 75:1170-9.